Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Carl Zeiss Meditec AG buy matumba

Start price
€13.97
02.09.11 / 50%
Target price
€17.70
14.02.12
Performance (%)
26.78%
End price
€17.71
14.02.12
Summary
This prediction ended on 14.02.12 with a price of €17.71. The prediction had a final performance of 26.78%. matumba has 50% into this prediction

Carl Zeiss Meditec AG is a German-based company that produces medical devices for ophthalmology and microsurgery. It operates in two segments: Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment includes diagnostic and surgical equipment for the anterior and posterior segments of the eye. The Microsurgery segment offers products for neurosurgery, spinal and ENT surgeries, and dental applications. The company has a global reach and serves customers in more than 115 countries through its subsidiaries and distribution network. Carl Zeiss Meditec has been listed on the Frankfurt and TecDAX stock exchanges since 2007.

Performance without dividends (%)
Name 1w 1m 1y 3y
Carl Zeiss Meditec AG -3.568% -3.568% -16.283% -32.453%
iShares Core DAX® 4.094% 3.543% 17.404% 20.326%
iShares Nasdaq 100 1.424% 0.512% 39.212% 55.365%
iShares Nikkei 225® -1.572% -4.633% 15.731% 2.146%
iShares S&P 500 1.822% 0.963% 30.396% 45.950%

Comments by matumba for this prediction

In the thread Carl Zeiss Meditec AG diskutieren
Prediction Buy
Perf. (%) 26.78%
Target price 17.700
Change
Ends at 14.02.12

guter durchblick

natürlich spielt der markt verrückt, aber bei deutschen aktien und noch dazu bei traditionellen firmen wie zeiss geb ich zuversichtlich meine trades ab

siehe auch:

11.02.2011 (www.4investors.de) - Im ersten Quartal des Geschäftsjahres 2010/2011 hat Carl Zeiss Meditec einen Umsatz von 185,2 Millionen Euro erzielt. Die Summe wächst gegenüber dem Vorjahreszeitraum um 18,6 Prozent. Operativ hat man den Gewinn von 18,7 Millionen Euro auf 24,0 Millionen Euro vor Zinsen und Steuern gesteigert. Bei der EBIT-Marge verzeichnet das TecDAX-notierte Unternehmen einen Zuwachs von 12 Prozent auf 13 Prozent. Für das Gesamtjahr peilt Carl Zeiss Meditec laut Aussagen von Konzernchef Ludwin Monz einen Umsatz zwischen 720 Millionen Euro und 750 Millionen Euro an.
( mic )


 

 

Prediction Buy
Perf. (%) 26.78%
Target price 17.700
Change
Ends at 14.02.12

(Zielkurs erreicht)

Stopped prediction by matumba for Carl Zeiss Meditec AG

buy
Carl Zeiss Meditec AG

Start price
Target price
Perf. (%)
€101.30
10.08.19
€169.00
04.11.21
83.17%
05.11.21

buy
Carl Zeiss Meditec AG

Start price
Target price
Perf. (%)
€21.75
09.10.13
€25.00
09.04.14
-0.10%
09.04.14